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Both classical DCs (cDCs) and monocyte-derived
DCs (Mo-DCs) are capable of cross-priming CD8+
T cells in response to cell-associated antigens.
We found that Ly-6ChiTREML4 monocytes can
differentiate into Zbtb46+ Mo-DCs in response to
granulocyte-macrophage colony-stimulating factor
(GM-CSF) and interleukin-4 (IL-4) but that Ly-6Chi
TREML4+ monocytes were committed to differen-
tiate into Ly-6CloTREML4+ monocytes. Differentia-
tion of Zbtb46+ Mo-DCs capable of efficient cross-
priming required both GM-CSF and IL-4 and was
accompanied by the induction of Batf3 and Irf4.
However, monocytes require IRF4, but not BATF3,
to differentiate into Zbtb46+ Mo-DCs capable of
cross-priming CD8+ T cells. Instead, Irf4/ mono-
cytes differentiate into macrophages in response to
GM-CSF and IL-4. Thus, cDCs and Mo-DCs require
distinct transcriptional programs of differentiation
in acquiring the capacity to primeCD8+ T cells. These
differences may be of consideration in the use of
therapeutic DC vaccines based on Mo-DCs.
INTRODUCTION
Cross-presentation functions in initiating cytolytic CD8+ T cell re-
sponses during viral infections (Joffre et al., 2012) and is medi-
ated by classical dendritic cells (cDCs) derived from the common
dendritic cell progenitor (Naik et al., 2007; Liu et al., 2007) and by
monocyte-derived dendritic cells (Mo-DCs) (Nierkens et al.,
2013). Efficient cross-presentation is carried out in vivo by a
CD24+ cDC subset requiring IRF8 and BATF3 (Brisen˜o et al.,
2014; Satpathy et al., 2012b), but the transcriptional require-
ments for Mo-DCs are undefined. In mice, monocytes can pro-
duce DCs under inflammatory conditions in vivo (Auffray et al.,
2009; Cheong et al., 2010) or upon ex vivo treatment with gran-2462 Cell Reports 15, 2462–2474, June 14, 2016 ª 2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://ulocyte-macrophage colony-stimulating factor (GM-CSF) (Inaba
et al., 1992, 1993; Caux et al., 1992). Human monocytes treated
ex vivo with GM-CSF and interleukin-4 (IL-4) also acquire DC
characteristics (Sallusto and Lanzavecchia, 1994; Romani
et al., 1994). Mo-DCs express CD11c andmajor histocompatibil-
ity complex class II (MHC-II) (Leo´n et al., 2004), aswell as theDC-
specific transcription factors ZBTB46 and L-MYC (Satpathy
et al., 2012a; KC et al., 2014). However, monocytes differentiated
with GM-CSF alone generate a heterogeneous population of
CD11c+ cells (Helft et al., 2015), resembling either macrophages
(GM-Macs, CD11b+MHC-IIlo) or DCs (GM-DCs, CD11b+MHC-
IIhi). GM-DCs cross-present soluble antigen more efficiently
than GM-Macs do (Helft et al., 2015).
Mo-DCs can promote TH1 and CD8
+ T cell responses (Leo´n
et al., 2007; Aldridge et al., 2009; Ji et al., 2013) but they differ
from cDCs in the antigen processing pathways they use (Segura
et al., 2009) and the phases of infection inwhich they are involved
(Ballesteros-Tato et al., 2010). Mo-DCs react distinctly from
cDCs in response to adjuvant (Langlet et al., 2012) and, unlike
cDCs, act independently of GM-CSF signaling in vivo during
steady state and immunization (Greter et al., 2012). Human
Mo-DCs generated ex vivo with GM-CSF and IL-4 can elicit
CD8+ T cell responses against tumor antigens (Nestle et al.,
1998; Ho¨ltl et al., 1999; Timmerman et al., 2002; Thurner et al.,
1999) and subdominant neoantigens (Carreno et al., 2015) and
they have been used in cancer vaccines (Palucka and Bancher-
eau, 2013; Carreno et al., 2015). Although CDPs have been sug-
gested as sources of DC vaccines (Guilliams and Malissen,
2015), the abundance and practical value of monocytes moti-
vates understanding their cross-presentation capacity for use
in future vaccine design.
How IL-4 regulates Mo-DC differentiation is still unclear. In
macrophages, IL-4 signaling induces M2 polarization (El Char-
touni et al., 2010) by STAT6 activation and induction of
Jumonji-domain-containing-3 (Jmjd3). JMJD3 functions as a de-
methylase of histone 3 lysine 27 (Ishii et al., 2009) and promotes
M2 polarization by regulating IRF4 expression (Satoh et al.,
2010). Loss of either JMJD3 or IRF4 impairs expression of M2
macrophage genes such as Arg1, IL13, and Fizz1 (Satoh et al.,.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Mo-DCs, but Not Sirp-a+ cDCs,
Cross-Present Cell-Associated Antigen as
Efficiently as CD24+ cDCs
(A andB) Splenic CD24+ and Sirp-a+ cDCs, BMLy-
6Chi monocytes, and Mo-DCs cultured in GM-
CSF + IL-4were purified by cell sorting. APCswere
co-cultured with CFSE-labeled OT-1 cells, and
the indicated number of OVA-loaded g-irradiated
Kb/Db/b2m/ (MHC-I TKO) splenocytes.
OT-I cells were analyzed after 3 days by flow cy-
tometry. (A) Representative flow cytometry anal-
ysis of OT-I proliferation after cross-presentation
assay. (B) Summary of OT-I proliferation after cell-
associated cross-presentation assay determined
as the percentage of CD44+ OT-I cells that had at
least one CFSE dilution. n = 3 biological replicates
per group; control: 1 3 105 g-irradiated MHC-I
TKO splenocytes without OVA.
(C) SIINFEKL peptide presentation by sorted
splenic CD24+ and Sirp-a+ cDCs, BM Ly-6Chi
monocytes, and Mo-DCs. OT-I cell proliferation
was analyzed by flow cytometry 3 days after cul-
ture. n = 2 biological replicates per group.
(D and E) Sorted splenic Sirp-a+ cDCs were
cultured in GM-CSF with or without IL-4 for 2 days
and tested for cross-presentation (D) as in (A) and
for SIINFEKL peptide presentation (E) as in (C).
Sorted splenic CD24+ and Sirp-a+ cDCs without
treatment were used as positive and negative
controls, respectively; n = 2 biological replicates
per group.
Error bars indicate SEM.2010). Whether similar actions of IL-4 and IRF4 occur duringMo-
DC differentiation has not been examined. In CD11b+ cDCs,
IRF4 is required for migration (Bajan˜a et al., 2012), survival in
mucosal tissues (Schlitzer et al., 2013; Persson et al., 2013),
and capacity to induce TH17 and TH2 responses (Gao et al.,
2013; Williams et al., 2013; Schlitzer et al., 2013; Persson
et al., 2013). Human Mo-DCs induce IRF4 in response to GM-
CSF and IL-4 (Lehtonen et al., 2005), but its function there is
undefined. In this study, we compared the transcriptional pro-
grams between cDCs and Mo-DCs for their ability to prime
T cells in response to cell-associated antigens, finding that
Mo-DCs do not require IRF8 and BATF3 like cDCs do but they
instead require IRF4.
RESULTS
IL-4 Is Required for Optimal Cross-Priming by GM-CSF-
Induced Mo-DCs
Splenic CD24+ cDCs, but not Sirp-a+ cDCs, efficiently cross-
primed T cells with cell-associated antigen (Figures 1A and
1B), as reported previously (den Haan et al., 2000; BeckerCell Ret al., 2014). As control, both cDC subsets
presented SIINFEKL peptide (Figure 1C).
Mo-DCs generated with GM-CSF and
IL-4 efficiently activated T cells in
response to cell-associated antigen and
SIINFEKL peptide, in contrast to Ly-6C+monocytes (Figures 1A–1C), as reported previously (Cheong
et al., 2010). UnlikeMo-DCs, sorted splenic Sirp-a+ DCs cultured
in GM-CSF with or without IL-4 did not cross-prime T cells to
cell-associated antigen (Figure 1D) but they presented SIINFEKL
peptide (Figure 1E). Thus, Mo-DCs, but not Sirp-a+ cDCs, are
able to cross-prime T cells to cell-associated antigens.
Monocytes cultured in GM-CSF produce a heterogeneous
population of MHC-IIhi GM-DCs and MHC-IIlo GM-Macs (Fig-
ure 2A), in agreement with a recent study (Helft et al., 2015).
MHC-IIhi GM-DCs expressed Zbtb46gfp (Satpathy et al.,
2012a), but MHC-IIlo GM-Macs did not (Figure 2A), consistent
with specific Zbtb46 expression in cDCs but not macrophages
(Meredith et al., 2012; Satpathy et al., 2012a). Addition of IL-4
with GM-CSF induced uniform Zbtb46gfp expression in both
MHC-IIhi and MHC-IIlo populations of CD11c+ cells (Figure 2A).
Both MHC-IIhi and MHC-IIlo cells that developed in GM-CSF
alone were weak cross-primers of cell-associated antigen, but
addition of IL-4 significantly enhanced their activity (Figure 2B)
to levels similar to those of CD24+ cDCs (Figures 1A and 1B).
All populations presented SIINFEKL peptide (Figure 2C). MHC-
IIlo (Figure 2D) and MHC-IIhi (Figure 2E) Mo-DCs differentiatedeports 15, 2462–2474, June 14, 2016 2463
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Figure 2. Mo-DCs Require IL-4 Treatment
during Differentiation for Optimal Cross-
Priming
(A) Ly-6Chi BM monocytes from Zbtb46gfp/+ mice
were sorted and cultured in GM-CSF with or
without IL-4 for 4 days and analyzed by flow
cytometry for expression of Zbtb46-GFP. Data
are representative of three independent experi-
ments.
(B) WT Mo-DCs were generated as in (A). CD11c+
Mo-DCs were then sorted as MHC-IIlo or MHC-IIhi
and co-cultured with CFSE-labeled OT-I cells and
OVA-loaded g-irradiatedMHC-I TKO splenocytes.
OT-I proliferation was analyzed by flow cytometry
after 3 days. Data are pooled from three inde-
pendent experiments, with at least four biological
replicates per group. Two-way ANOVA with
Sidak’s multiple comparison test. ***p < 0.001; ns,
not significant.
(C) SIINFEKL peptide presentation by Mo-DCs to
CFSE labeled OT-I cells. OT-I proliferation was
analyzed on the third day as in (B). n = 2 biological
replicates per group.
(D and E) Mo-DCs were sorted as in (B) and co-
cultured with g-irradiated CFSE-labeled CD45.1+
splenocytes for 16 hr. Uptake of apoptotic cells
was determined as the percentage of CD45.2+
CD45.1CD11c+ Mo-DCs that were CFSE+. n = 2
biological replicates per group.
Error bars indicate SEM.with GM-CSF alone or with IL-4 showed similar uptake of
apoptotic cells. Thus, IL-4 signaling during GM-CSF-induced
monocyte differentiation induces Zbtb46 expression in MHC-
IIlo cells and increases cross-priming in both MHC-IIhi and
MHC-IIlo cell populations.
Expression of TREML4 and NUR77 Identifies Monocytes
Lacking Mo-DC Potential
TREML4, a member of the triggering receptor expressed on the
myeloid cells family (Ford and McVicar, 2009), is induced during
heme-mediated differentiation of macrophages frommonocytes
and bonemarrow (BM) progenitors (Haldar et al., 2014). TREML4
is expressed on CD24+ cDCs, monocytes (Hemmi et al., 2012),
and macrophages, where it regulates TLR7 signaling amplifica-
tion (Ramirez-Ortiz et al., 2015). Ly-6Chi monocytes were hetero-
geneous for TREML4 expression, but Ly-6Clo monocytes were
uniformly TREML4 positive (Figure 3A). Only Ly-6Chi TREML4
monocytes were able to induce Zbtb46gfp expression in
response to GM-CSF and IL-4, whereas Ly-6Chi TREML4+
monocytes and Ly-6Clo TREML4+ monocytes could not (Fig-
ure 3B). Thus, TREML4maymark the commitment of monocytes
to the Ly-6Clo monocyte and macrophage lineages. Gene
expression profiling suggested that Ly-6Chi TREML4+ mono-
cytes were an intermediate stage of differentiation between Ly-
6Chi TREML4 and Ly-6Clo monocytes (Figure 3C). In Ly-6Chi2464 Cell Reports 15, 2462–2474, June 14, 2016TREML4 monocytes, expression of Ccr2 was 3-fold higher
and 10-fold higher compared to Ly-6C+ TREML4+ and Ly-6Clo
TREML4+ monocytes, respectively, while Treml4 expression
was about 4-fold higher in Ly-6Chi TREML4+ monocytes and
6-fold higher in Ly-6Clo TREML4+ monocytes, relative to Ly-
6Chi TREML4 monocytes (Figure 3C).
NUR77 (encoded by Nr4a1) is required for the development of
Ly-6Clo monocytes (Martı´nez-Gonza´lez and Badimon, 2005;
Hanna et al., 2011). Our analysis of Nr4a1-GFP reporter mice
(Moran et al., 2011) shows that TREML4 expression increased
along with Nr4a1 (Figure 3D). Nr4a1-GFP was absent in Ly-
6Chi TREML4 monocytes but was expressed at intermediate
levels in all Ly-6Chi TREML4+ monocytes and at high levels in
all Ly-6Clo TREML4+ monocytes (Figure 3D). Then, we tested
the DC potential of monocytes expressing different levels of
Nr4a1 (Figure 3E). Ly-6C+Nr4a1-GFPmonocytes differentiated
into Mo-DCs in response to GM-CSF and IL-4 (Figure 3E). In
contrast, Ly-6C+ Nr4a1-GFP+ monocytes and Ly-6Clo Nr4a1-
GFP+ monocytes were unable to differentiate into CD11c+
MHC-II+ Mo-DCs (Figure 3E). Nr4a1-deficient monocytes could
not develop into Ly-6Clo monocytes, as reported (Moran et al.,
2011), but could develop into Mo-DCs (Figure 3F). Unsupervised
analysis using SPADE (Qiu et al., 2011) reconstituted the succes-
sive steps of monocyte differentiation in vivo (Figure S1, related
to Figure 3). Thus, Ly-6Chi TREML4 Nr4a1-GFP monocytes
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are the last stage of monocyte differentiation that retains poten-
tial for Mo-DC development.
IL-4 Induces BATF3 and IRF4 during Mo-DC
Differentiation
We examined gene expression microarrays of Ly-6Chi TREML4
and Ly-6Clo monocytes, Mo-DCs cultured with or without IL-4,
and splenic CD24+ and Sirp-a+ cDCs. Several transcription
factors were increased when Mo-DCs were differentiated with
GM-CSF and IL-4 as compared to monocytes or Mo-DCs
cultured in GM-CSF alone (Figure 4A). Specifically, Batf3 was
induced by GM-CSF and IL-4 by 10-fold and 4-fold relative to
monocytes and Mo-DCs cultured with GM-CSF alone, respec-
tively. In addition, Irf4 was induced more than 25-fold relative
to monocytes and 2-fold relative to Mo-DCs cultured with GM-
CSF (Figures 4A and 4B), as reported in human Mo-DCs (Lehto-
nen et al., 2005). Two other factors, Nr4a3 (DeYoung et al., 2003)
and Vdr (Yoshizawa et al., 1997; Li et al., 1997), were induced,
but these have not been associated with antigen presentation.
In contrast, Batf3 is required for the development of cDCs
capable of cross-presentation (Hildner et al., 2008; Torti et al.,
2011), and Irf4 was shown to be required for MHC-II expression
in GM-DCs (Vander Lugt et al., 2014). Mo-DCs induced Batf3,
but not Batf or Batf2, to levels equivalent to those of both splenic
CD24+ and Sirp-a+ cDCs (Figure 4C). Likewise, Mo-DCs ex-
pressed Irf4 to levels similar to those of Sirp-a+ cDCs (Figure 4C).
Also, IL-4 increased IRF4 expression in Mo-DCs (Figure 4D). In
summary, IL-4 induced both BATF3 and IRF4 during Mo-DC
differentiation.
Cross-Priming by Mo-DCs Is Independent of BATF3
To examine Mo-DC differentiation and function, we used mono-
cytes from Batf, Batf2, and Batf3 triple-knockout mice (Batf-
TKO), since Batf and Batf2 can compensate for Batf3 in CD24+
cDC development (Tussiwand et al., 2012). Mo-DCs developed
normally from Batf-TKO monocytes (Figure 5A), with normal
expression of IRF4 and IRF8 (Figure 5B). As reported (Tussiwand
et al., 2012), Batf-TKO lacked splenic CD24+ cDCs but retained
Sirp-a+ cDCs (Figure 5A). We found no difference in cross-prim-
ing between wild-type (WT) and Batf-TKO Mo-DCs over a range
of antigen concentrations or in presentation of SIINFEKL peptideFigure 3. TREML4 Identifies a Subset of Ly-6Chi Monocytes Committe
(A) Flow cytometry of bone marrow (BM) and peripheral blood (PB) cells from
CD135CD11cMHC-IICD115+CD11b+ live cells. PB monocytes were gated a
representative of three independent experiments.
(B) Ly-6ChiTREML4, Ly-6ChiTREML4+, and Ly-6CloTREML4+ monocytes were so
analyzed by flow cytometry for Zbtb46-GFP expression. Data are representative
(C) Gene expression microarray analysis of sorted Ly-6ChiTREML4, Ly-6ChiTR
3-fold different between Ly-6ChiTREML4 and Ly-6CloTREML4+ monocytes.
(D) Flow cytometry analysis of Nur77-GFP expression in the indicated monocyte
gated as in (A).
(E) Sorted Ly-6ChiNr4a1(Nur77)-GFP, Ly-6ChiNur77-GFP+, and Ly-6CloNur77-G
Left panels show representative two-color histograms for CD11c and MHC-II exp
replicate. n = 6 biological replicates from two independent experiments.
(F) Sorted Ly-6ChiTREML4 PB monocytes from Nr4a1/ and WT littermate co
sentative of three independent experiments.
(G) Flow cytometry analysis of PB fromWT and Nr4a1/mice. Cells were gated
replicate; two-way ANOVA with Sidak’s multiple comparison test.
**p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant. See also Figure S1.
2466 Cell Reports 15, 2462–2474, June 14, 2016(Figures 5C and 5D). Splenic Batf-TKO Sirp-a+ DCs did not
cross-prime but could present SIINFEKL peptide (Figures 5E
and 5F). Thus, development and cross-priming of Mo-DCs was
independent of BATF3.
IRF4 Is Required for Development of In-Vitro-Derived
Mo-DCs but Not for Sirp-a+ cDCs
IRF4 is required for the migration and homeostasis of Sirp-a+
cDCs (Bajan˜a et al., 2012; Schlitzer et al., 2013; Persson et al.,
2013) and promotes MHC-II expression by BM-derived GM-
DCs (Vander Lugt et al., 2014), but its role in priming of CD8+
T cells by Mo-DCs is unknown. Mo-DCs derived from Irf4/
Ly-6Chi TREML4 monocytes were inactive for cross-priming
(Figures 6A and 6B). In contrast, Irf4/ splenic CD24+ cDCs
were as efficient as WT CD24+ DCs in cross-priming OT-I cells
(Figures 6C and 6D). The uptake of apoptotic cells was similar
between WT and Irf4/ Mo-DCs (Figure 6E). Mo-DCs lacking
IRF4 did not express MHC-II, as reported previously (Vander
Lugt et al., 2014), but expressed normal MHC class I (MHC-I)
levels (Figure 6F). However, they were unable to induceOT-I pro-
liferation with SIINFEKL peptide (Figure 6G).
Unlike WT Mo-DCs, Irf4/ monocytes failed to induce
Zbtb46-GFP and, instead, acquired expression of F4/80 fol-
lowing treatment with GM-CSF and IL-4 (Figure 7A). IRF4 was
not required for Zbtb46 expression in CD24+ or Sirp-a+ splenic
cDCs (Figure 7A). By contrast, Zbtb46-deficient Mo-DCs ex-
pressed normal levels of MHC-II and IRF4 (Figure 7B). Consis-
tent with the lack of MHC-II and Zbtb46 expression, the normal
DC morphology of Mo-DCs was not seen in Irf4/ Mo-DCs,
which, instead, had the appearance ofmacrophages (Figure 7C),
suggesting that IRF4 may be required for the induction of a
broader DC transcriptional program in Mo-DCs beyond MHC-II
gene expression.
To determine the identity of cells originating from IRF4-defi-
cient monocytes cultured with GM-CSF and IL-4, we performed
microarray analysis of WT and Irf4/ Mo-DCs (Figures 7D and
7E). Consistent with the macrophage identity observed by flow
cytometry and microscopy, Irf4/ monocytes cultured in GM-
CSF and IL-4 induced high expression of macrophage-specific
genes such asMertk, Tlr4, and Tlr7 (Gautier et al., 2012) and, un-
like WT Mo-DCs, failed to induce DC-associated genes such asd to Macrophage-Lineage Differentiation
WT mice. BM monocytes were gated as Ter-119B220Ly-6GCD117
s CD45.2+B220Ter-119MHC-IILy-6GCD115+CD11b+ live cells. Data are
rted from PB of Zbtb46gfp/+mice, cultured in GM-CSF and IL-4 for 3 days, and
of three independent experiments.
EML4+, Ly-6CloTREML4+ PB monocytes. Shown are genes that were at least
populations from peripheral blood of Nr4a1-GFP mice. Monocytes were pre-
FP+ peripheral blood monocytes from Nr4a1-GFP mice were cultured as in (B).
ression. Right panel shows summarized data; each dot represents a biological
ntrols were cultured as in (B) and analyzed by flow cytometry. Data are repre-
as in (A). Right panel shows summarized data; each dot represents a biological
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Figure 4. Mo-DCs Induce Expression of
Batf3 and Irf4 in Response to IL-4
(A) Gene expression microarray analysis of Ly-
6Chi monocytes and Mo-DCs differentiated with
GM-CSF alone or GM-CSF and IL-4. Shown is the
ratio of expression inMo-DCs generated with GM-
CSF and IL-4 versus that of Mo-DCs generated
with GM-CSF alone (horizontal axis) plotted
against the ratio of expression in Mo-DCs gener-
ated with GM-CSF and IL-4 versus that in
monocytes (vertical axis) for all transcription-
factor-encoding genes.
(B) Gene expression of transcription factors
induced at least 2-fold in Mo-DCs cultured with
IL-4 relative to Mo-DCs cultured with GM-CSF
alone. Shown are biological replicates for each cell
lineage.
(C) Relative expression of Batf, Batf2, Batf3, and
Irf4 from microarrays of the indicated cell type.
(D) Representative intracellular flow cytometry
analysis of sorted Ly-6ChiTREML4 BM mono-
cytes cultured in GM-CSF with or without IL-4. Ly-
6C+BMmonocytes are shown as control. Data are
representative of three independent experiments.
Error bars indicate SEM.Kmo, Traf1, and Slamf7 (Miller et al., 2012) (Figure 7D). Since
IRF4 has been previously implicated in the development of
splenic Sirp-a+ cDCs (Suzuki et al., 2004), we asked whether
IRF4 regulated a similar genetic program in both Mo-DCs
and splenic Sirp-a+ cDCs. Comparison of the microarrays of
WT and Irf4/ Mo-DCs showed 747 genes to be differentially
expressed by at least 3-fold between these two populations
(Figure 7E). However, only 49 of those targets were also at
least 3-fold different between WT and Irf4/ Sirp-a+ cDCs (Fig-
ure 7E), suggesting that Mo-DCs, but not splenic Sirp-a+
cDCs, require IRF4 for their development. We identified CD86
to be specifically downregulated in Mo-DCs, but not Sirp-a+
cDCs, lacking Irf4. We confirmed this result by assaying the
expression of CD86 on WT and Irf4/ splenic cDCs and Mo-
DCs activated with lipopolysaccharide (LPS). Only Mo-DCs,
not CD24+ or Sirp-a+ cDCs, required IRF4 for CD86 expression
(Figures 7F and 7G). Altogether, these results indicate a specific
requirement for IRF4 by monocytes for their differentiation into
DC-like cells.Cell ReDISCUSSION
Vaccines based onMo-DCs can enhance
immune responses against human mela-
noma (Carreno et al., 2015). Mo-DCs
have been generated either in culture of
GM-CSF alone or with IL-4 (Linette and
Carreno, 2013). We show that IL-4 aug-
ments expression of Zbtb46 and Irf4
and that Irf4 is required for monocytes
to differentiate into DCs. Mo-DCs can
cross-prime CD8+ T cells for cell-associ-
ated antigen as efficiently as CD24+
cDCs. We show that Mo-DCs rely ona distinct transcriptional program compared with cDCs in
acquiring the ability to prime CD8+ T cells. Cross-presenting
Mo-DCs require IRF4 but not BATF3, while cross-presenting
cDCs require BATF3 but not IRF4.
Circulating Ly-6Chi monocytes can differentiate into either Mo-
Macs, Mo-DCs, or Ly-6Clo ‘‘patrolling’’ monocytes. NUR77 is
required for differentiation of Ly-6Chi monocytes into patrolling
monocytes (Hanna et al., 2011) but not into Mo-DCs (Figure 3F).
We find that Ly-6Chi monocytes that express NUR77 or TREML4
lack Mo-DC potential. In CD8+ T cells, NUR77 may inhibit IRF4
expression (Nowyhed et al., 2015), suggesting that it may act
similarly in Ly-6Chi TREML4+ monocytes to repress IRF4 and,
thus, Mo-DC development.
The biochemical basis for cross-presentation by different cells
remains incompletely understood. Several proteins implicated in
cross-presentation have been analyzed only in cells generated
fromBMcells treated with GM-CSF alone (Joffre et al., 2012; Se-
gura and Amigorena, 2015). In this setting, NOX2 (Savina et al.,
2006, 2009), Rac2 (Savina et al., 2009) and VAMP8 (Matheoudports 15, 2462–2474, June 14, 2016 2467
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Figure 5. Mo-DCsDoNotRequire BATF3 for
Differentation into APCs Capable of Cross-
Priming
(A) Flow cytometry analysis of splenocytes
and Mo-DCs generated with GM-CSF and IL-4
from WT and Batf/Batf2/Batf3/ (Batf-TKO)
mice. Splenic cDCs are pre-gated as B220
CD11c+MHC-II+ cells. Mo-DCs are gated as
Ly-6C cells. Data are representative of two in-
dependent experiments.
(B) Intracellular flow cytometry analysis for IRF4
and IRF8 in WT and Batf-TKO Mo-DCs. Data
are representative of three independent experi-
ments.
(C) Cross-presentation of cell-associated antigen
by WT and Batf-TKO Mo-DCs. Percent prolifera-
tion was determined as the percentage of CD44+
OT-I cells that had undergone at least one CFSE
dilution. n = 3 biological replicates per group;
control: 1 3 105 g-irradiated MHC-I TKO spleno-
cytes without OVA.
(D) SIINFEKL peptide presentation by WT and
Batf-TKO Mo-DCs. OT-I proliferation was
analyzed by flow cytometry, as in (C), after
3 days of culture. n = 2 biological replicates per
group.
(E) Cell-associated cross-presentation assay by
Batf-TKO Sirp-a+ cDCs, as in (C). Splenic WT
CD24+ and Sirp-a+ cDCs were used as controls.
(F) SIINFEKL peptide presentation by WT CD24+
and Sirp-a+ cDCs and Batf-TKO Sirp-a+ cDCs, as
in (D), n = 2 biological replicates per group.
Error bars indicate SEM.et al., 2013) were shown to regulate acidification of phagosomes
in GM-DCs, suggesting that they act to preserving antigens from
complete degradation. While NOX2 and RAC2 also regulate
phagosomal acidification in CD8+ cDCs (Savina et al., 2009),
only NOX2, but not RAC2, deficiency reduced CD8+ cDC
cross-presentation of soluble antigen. RAB11A (Nair-Gupta
et al., 2014), RAB3B (Zou et al., 2009), and SEC22B (Cebrian
et al., 2011), which regulate vesicular trafficking, were shown
to promote cross-presentation but were studied using BM cul-
tures treated with GM-CSF or in the DC2.4 cell line. In our
studies, Mo-DCs generated with GM-CSF alone were relatively
inefficient in the cross-priming of cell-associated antigen,
compared with CD8+ cDCs and Mo-DCs generated with both
GM-CSF and IL-4 (Figure 2B).
Other known proteins such as ERAP1 (Firat et al., 2007) and
IRAP (Segura et al., 2009; Saveanu et al., 2009) may be
also be involved in cross-presentation. ERAP1 was required
in vivo but not in GM-CSF BM-derived cells (Firat et al., 2007),
while IRAP was required for both in vivo and in vitro cross-
priming of CD8+ T cells to cell-associated antigen (Saveanu
et al., 2009). IRAP was required for cross-presentation of soluble
antigen only in inflammatory Mo-DCs generated in vivo and
not in CD24+ DCs (Segura et al., 2009). Alternately, unknown2468 Cell Reports 15, 2462–2474, June 14, 2016proteins may remain unidentified that differentially act in cross-
presentation.
EXPERIMENTAL PROCEDURES
Mice
Zbtb46gfp/+ mice (Satpathy et al., 2012a) were backcrossed to C57BL/6J for
at least eight generations. Batf/Batf2/Batf3/ (Batf-TKO), Irf8/, and
Irf4/ mice have been described previously (Tussiwand et al., 2012;
Grajales-Reyes et al., 2015). The following mice were purchased from
Jackson Laboratory: Nr4a1/ (B6;129S2-Nr4a1tm1Jmi/J), OT-I (C57BL/6-Tg
(TcraTcrb)1100Mjb/J), and CD45.1+ (B6.SJL-Ptprca Pepcb/BoyJ). Nr4a1gfp/+
mice were a gift from Chyi-Song Hsieh, and Kb/Db/b2m/ mice
(MHCI-TKO; Lybarger et al., 2003) were a gift from Herbert W. Virgin IV and
Ted Hansen, Washington University in St. Louis. Mice, except Batf-TKO
(129/SvEvTac), were maintained on the C57BL/6 background. All mice were
housed in a specific pathogen-free animal facility following institutional guide-
lines with protocols approved by the animal studies committee at Washington
University in St. Louis. Experiments were performed with mice 8–12 weeks of
age using sex-matched littermates.
Antibodies and Flow Cytometry
Cells were stained at 4C in MACS buffer (PBS with 0.5% BSA and 2 mM
EDTA) with CD16/32 Fc block (Becton Dickinson [BD] clone 2.4G2).
The following antibodies were purchased from BD: CD11b (M1/70); CD45.2
(104); CD135 (A2F10.1); MHC-II (M5/114.15.2); and Ly-6C (AL-21). The
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Figure 6. Mo-DCs Require IRF4 for Cross-Priming CD8+ T Cells to Cell-Associated Antigen
(A and B) Cross-presentation of cell-associated antigen by WT and Irf4/ Mo-DCs. OT-I cell proliferation was analyzed by flow cytometry 3 days after culture.
(A) Representative two-color histograms of OT-I cell proliferation after cross-presentation assay. (B) Summary of cell-associated cross-presentation by WT and
Irf4/Mo-DCs. Percent proliferation of OT-I cells was determined as CD44+ OT-I cells that had undergone at least one CFSE dilution. Data are pooled from six
biological replicates per group; control: 1 3 105 g-irradiated MHC-I TKO splenocytes without OVA.
(C) Cross-presentation of cell-associated antigen by sorted CD24+ and Sirp-a+ DCs from spleens of WT and Irf4/mice as in (A); n = 2 biological replicates per
group.
(D) SIINFEKL peptide presentation by splenic CD24+ and Sirp-a+ DCs from WT and Irf4/ mice; n = 2 biological replicates per group.
(legend continued on next page)
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following were purchased from eBioscience: CD4 (GK1.5); CD8a (53-6.7);
CD11b (M1/70); CD45.1 (A20); CD44 (IM7); CD117 (2B8); CD115 (AFS98);
CD11c (N418); CD24 (M1/69); CD172a (P84); Ly-6C (HK1.4); Ly-6A/E (D7);
Ly-6G (IA8); Siglec-H (eBio440C); Ter-119 (Ter-119); CD105 (MJ7/18); Irf8
(V3GYWCH); CD45R (RA3-6B2); NK1.1 (PK136); Irf4 (3E4); and 7-AAD viability
staining solution. The following were purchased from Tonbo Biosciences:
CD45.1 (A20); and CD11c (N418). The following were purchased from
BioLegend: CD8a (53-6.7); CD45.2 (104); CD115 (ASF98); Ly-6G (IA8); TCR
Va2 (B20.1); and TREML4 (16E5). The following were purchased from
ThermoFisher Scientific: TCR Va2 (B20.1) and the LIVE/DEAD Fixable Aqua
Dead Cell Stain Kit. Carboxyfluorescein succinimidyl ester (CFSE) was pur-
chased from Sigma.
Anti-biotin and anti-B220 microbeads were purchased from Miltenyi Biotec.
Cellswere fixedandpermeabilized for intracellular stainingof IRF4and IRF8us-
ing the FoxP3/TranscriptionBuffer Set (eBioscience). Cellswere sortedon aBD
FACSAria Fusion flow cytometer (BD) and with FlowJo software (Tree Star).
Isolation and Culture of BM Cells and Splenic DCs
Femurs, pelvises, and tibias were crushed using a mortar and pestle in MACS
buffer, filtered through a 70-mm strainer, purified on Histopaque-119 gradient,
and depleted of Ly-6G- and B220-expressing cells with biotinylated anti-Ly-
6G and B220 antibodies and anti-biotin microbeads (Miltenyi Biotec). BM
monocytes were identified as LinSiglecHLy-6GMHC-IIloCD11cCD117
CD135CD115+ and sorted as Ly-6ChiTREML4 or Ly-6CloTREML4+ for
microarray analysis. Lin includes B220, CD105, NK1.1, and Ter-119. Blood
monocytes were defined as Ter-119CD45.2+MHC-IIloLy-6GCD115+ and
segregated based on Ly-6C and TREML4 expression. Cells were sorted
into Iscove’s modified Dulbecco’s medium + 10% fetal calf serum (FCS)
kept at 4C. Spleens were minced and digested for 45 min at 37C with
stirring in 5 ml of complete media with 250 mg/mL collagenase B (Roche)
and 30 U/mL DNase I (Sigma-Aldrich). Red blood cells were lysed with ACK
(ammonium-chloride-potassium) lysis buffer, and splenocytes were passed
through a 70-mm strainer. CD24+ cDCs were defined as B220CD11c+MHC-
II+CD24+CD172a. Sirp-a+ cDCs were defined as B220CD11c+MHCII+
CD24CD172a+. For Mo-DC differentiation, sorted Ly-6C+ TREML4 mono-
cytes from BM or peripheral blood were cultured (0.25 3 105–0.5 3 105
cells/mL) at 37C in complete media with GM-CSF and IL-4 (20 ng/mL; Pepro-
tech) for 3-4 days. Loosely adherent Mo-DCs were harvested by gentle
pipetting. Sorted Sirp-a+ cDCs were cultured in 20 ng/mL of GM-CSF and
IL-4 for 48 hr. For induction of CD86, sorted CD24+ and Sirp-a+ cDCs, as
well as Mo-DCs, were cultured with LPS (1 ng/mL) for 16 hr.
Microscopy
Cytospins of sorted Mo-DCs generated from GM-CSF and IL-4 culture of Ly-
6C+TREML4– monocytes were stained with Wright-Giemsa stain using a
Hema 3 kit (Fisher Scientific). Images were acquired at room temperature
with an Axioskop microscope (objective: 1003, 1.25, oil) using an Axiocam
ICc3 camera (Zeiss).
Gene Expression Microarray Analysis
Total RNAwas extracted from purified splenic cDCs,Mo-DCs, andmonocytes
from BM and peripheral blood using the RNAqueous-Micro Kit (Ambion). RNA
was amplified using the Ovation Pico WTA Sytem (NuGEN) and hybridized to
GeneChip Mouse Gene 1.0 ST microarrays (Affymetrix). Data were processed
using robust multiarray average summarization and quartile normalization us-
ing ArrayStar software, version 5 (DNASTAR). Expression values for cell line-
ages were averaged from biological duplicates, except for WT CD24+ cDCs(E) Apoptotic cell uptake byWT and Irf4/Mo-DCs after 16 hr of culture. Cells wer
n = 2 biological replicates per group.
(F) Flow cytometry analysis of WT and Irf4/ ex-vivo-derived Mo-DCs and sple
One-color histograms show MHC-I expression for the indicated populations. Cell
biological replicates.
(G) SIINFEKL peptide presentation assay by WT and Irf4/ Mo-DCs. OT-I prolife
ANOVA with Sidak’s multiple comparison test.
Error bars indicate SEM. **p < 0.01; ****p < 0.0001; ns, not significant.
2470 Cell Reports 15, 2462–2474, June 14, 2016and peripheral blood monocyte subsets, which were from one biological
sample.
Antigen Presentation Assays
Splenic OT-I cells were sorted as B220CD11cCD45.1+TCR-Va2+CD4
CD8a+ to > 95% purity, labeled with CFSE, and plated at a density of
12.5 3 105 cells/mL. Splenocytes from MHC-I TKO mice were processed as
described earlier. OVA loading of MHC-I TKO splenocytes has been described
previously (Carbone and Bevan, 1990). Splenocytes (2.53 107/mL) were incu-
bated in hypertonic medium (RPMI 1640, 0.5 M sucrose, 10% w/v polyethy-
lyne glycol, 10 mM HEPES [pH 7.2]) with 5 mg OVA (Worthington) for 10 min
at 37C. Cells were diluted 10-fold with hypotonic media (60% fetal bovine
serum [FBS], 40% sterile water) and incubated for 2 min at 37C. Cells were
washed with PBS and irradiated (13.5 Gy). Sorted splenic CD24+ and Sirp-a+
cDCs, as well as Mo-DCs (12.5 3 105 cells/mL), were co-cultured with
CFSE-labeled OT-I cells (12.5 3 105 cells/mL) and OVA-loaded MHC-I TKO
cells (2.5 3 105–25.0 3 106 cells/mL). For peptide presentation, 2.5 3 104 an-
tigen-presenting cells (APCs) were cultured with SIINFEKL peptide (1.0 3
103–1.0 ng/mL) for 45 min in complete media at 37C, washed twice, and
cultured with 2.5 3 104 CFSE-labeled OT-I cells. Cells were cultured at 37C
for 3 days and analyzed by flow cytometry. OT-I proliferation was determined
as the percentage of CD45.1+CD8a+TCR-Va2+CD44+ cells that had under-
gone at least one CFSE dilution.
Phagocytosis Assay
To prepare target cells, CD45.1+ splenocytes were harvested as described
earlier, loaded with CFSE, and g-irradiated (13.5 Gy). Sorted CD45.2+ Mo-
DCs (12.5 3 105 cells/mL) were co-cultured with CFSE-labeled irradiated
splenocytes (2.53 105–25.03 105 cells/200 mL) for 16 hr at 37C. After culture,
Mo-DCs were washed and stained for CD45.2, CD45.1, CD11c, Ly-6C, Aqua,
and MHC-II. Percent phagocytosis was determined as the percentage of live
(Aqua) singlet Mo-DCs (CD45.1CD45.2+Ly-6CCD11c+) that were CFSE
positive.
Statistical Analysis
Statistical analyseswere performed using a two-way ANOVAwith Sidak’smul-
tiple comparison test unless otherwise specified. All statistical analyses were
performed using Prism (GraphPad Software).
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